Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.88 |
| ▸ | HTT | P42858 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | POLB | P06746 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303527 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3971438 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8502340 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8583228 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL7953663 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | claimed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | TMEM14C, ARFGEF1, NPFFR1 | PKM 2534/4885HTT 993/4885ALDH1A1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.